The Effect of Abiraterone on the Metabolism of Oxycodone
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Prostate cancer often leads to bone metastases, which require adequate pain management with opioids such as oxycodone. This study investigates whether abiraterone - a drug used in the treatment of prostate cancer - affects the pharmacokinetics of oxycodone in order to improve pain management.
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: f
View:
• Diagnosed prostate cancer;
• Males aged 18 years or older;
• Treated with abiraterone 1000 mg once daily for at least 10 days (abiraterone arm).
• Not treated with abiraterone 1000 mg once daily for at least 10 days (control arm).
Locations
Other Locations
Netherlands
Deventer Ziekenhuis
RECRUITING
Deventer
Contact Information
Primary
Frank Jansman, Prof. dr.
f.jansman@dz.nl
+31570 53 60 00
Backup
Lotte Hulskotte, drs.
l.hulskotte@dz.nl
+31631451719
Time Frame
Start Date: 2024-04-12
Estimated Completion Date: 2026-01-30
Participants
Target number of participants: 29
Treatments
Other: Control group
Receive 15 mg oxycodone (direct release) without the use of abiraterone. The plasma concentration of oxycodone, noroxycodone, oxymorphone and noroxymorphone is measured. In addition, one blood sample is drawn for determine patient characteristics and genotyping of CYP3A4 and CYP2D6 is determined.
Other: Abiraterone group
Receive 15 mg oxycodone (direct release) and abiraterone. The plasma concentration of oxycodone, noroxycodone, oxymorphone and noroxymorphone is measured. In addition, one blood sample is drawn for determine patient characteristics, the serum through concentration of abiraterone and genotyping of CYP3A4 and CYP2D6 are determined.
Related Therapeutic Areas
Sponsors
Leads: Deventer Ziekenhuis